Dr. Samir Parekh, MD
Oncologist
At a glance
5.00 stars (6 reviews)
100% are satisfied with this provider ·
Has 20+ years of experience
Graduated from K.J. Somaiya Medical College, Bachelor of Medicine, Bachelor of Surgery
Works at Mount Sinai Cancer
Affiliated with The Mount Sinai Hospital
Samir Parekh does not participate in Zocdoc to offer online booking at this time
Areas of expertise
This doctor's experience enhances their expertise in similar cases. Below are the conditions or surgeries they treat most frequently.
Multiple myeloma
Multiple myeloma
Other popular visit reasons
Multiple Myeloma
Oncology Consultation
Multiple Myeloma
Oncology Consultation
More about Dr. Samir Parekh, MD
Mount Sinai Oncology will work with patients on a case by case basis to review insurance coverage. Patients can expect a call from the office after booking to discuss these details.
The practice will try to accommodate the time selected however the appointment date and time may need to adjusted to better suit the specific patient case.
Dr. Parekh's team is studying Mantle Cell Lymphoma (MCL), a rare and usually fatal subtype of non-Hodgkin’s lymphoma, in collaboration with a Phase II clinical trial at the NIH. The specific aims of this project are to (1) Identify aberrantly methylated genes in MCL as compared to normal naïve B cells (2) Identify differentially methylated genes associated with Bortezomib resistance in MCL (3) Construct a multi-platform model predictive for patient outcomes in MCL. These correlative studies are likely to improve our molecular understanding of pathways involved in lymphoma pathogenesis, and identify signatures useful for better selection of patients for epigenetic therapy in future prospective trials. So far, results using array based methylation and gene expression analysis of primary MCL have demonstrated (a) Widespread genomic hypomethylation in comparison to Naïve B cells which are the cell of origin for these lymphomas. (2) Silencing of tumor suppressor genes including MLF1, CDKN2B and PCDH8 that are amenable to therapeutic induction by epigenetic drugs (c) Novel hypomethylated genes e.g. CD37 are over-expressed and amenable to therapeutic targeting witha novel agents.
Education & experience
Education
Medical School - K.J. Somaiya Medical College, Bachelor of Medicine, Bachelor of Surgery
Cook County Hospital, Residency in Internal Medicine
Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, Fellowship in Hematology and Oncology
Practice
Mount Sinai Cancer
Affiliation
The Mount Sinai Hospital
Certifications
American Board of Internal Medicine
Hematology (Internal Medicine)
Awards and publications
2005 Young Investigator Award ASCO
First Overall and Highest Rank in General Internal Medicine K.J. Somaiya Medical College
Young Investigator Travel Award ECOG
Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA, Parekh S. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 May; 18(9).
Wetzler M, Thomas DA, Wang ES, Shepard R, Ford LA, Heffner TL, Parekh S, Andreeff M, O'Brien S, Kantarjian HM. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clinical lymphoma, myeloma & leukemia 2013 Aug; 13(4).
Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A, Singhal SB. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. Journal of immunology (Baltimore, Md. : 1950) 2013 Mar; 190(6).
Thirukonda V, Petrich A, Parekh S. Classical Hodgkin lymphoma and spontaneous regression. Clinical advances in hematology & oncology : H&O 2012 Nov; 10(11).
Background
Languages spoken
English
Gender
Male
NPI number
#1497835987
Samir Parekh does not participate in Zocdoc to offer online booking at this time
Patient reviews
All reviews have been submitted by patients after interacting with the practice.
Overall rating
5.00
Your trust is our top concern, so providers can't pay to alter or remove reviews. We also don't publish reviews that contain any private patient health information. Learn more here
6 reviews
Most relevant
More than 1 year agoInitials hiddenSource: Partner
More than 1 year agoInitials hiddenSource: Partner
More than 1 year agoInitials hiddenSource: Partner
More than 1 year agoInitials hiddenSource: Partner
More than 1 year agoInitials hiddenSource: Partner
More than 1 year agoInitials hiddenSource: Partner
Which hospital is Dr. Samir Parekh affiliated with?
Dr. Samir Parekh is affiliated with The Mount Sinai Hospital.
What practice does Dr. Samir Parekh work with?
Dr. Samir Parekh works with Mount Sinai Cancer.
Which board certifications does Dr. Samir Parekh have?
Dr. Samir Parekh is certified by American Board of Internal Medicine and Hematology (Internal Medicine).
What languages does Dr. Samir Parekh speak?
Dr. Samir Parekh speaks English.